Physician

Brian Andrew Holloway, M.D.

According to 2025 Medicare claims, Brian Holloway, M.D. (NPI: 1558781807) practices dermatology in the Santa Cruz-Watsonville, CA market, with the plurality of this provider's patient population coming from Santa Cruz, CA. This provider's primary affiliated billing organization is SUTTER BAY MEDICAL FOUNDATION (NPI: 1013950807; TIN: 941156581) and primary practice location at 95073-2000. Holloway is affiliated with the Sutter Medicare Direct (ACO ID: A5279), participating under the MSSP model.

Holloway's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,548 traditional Medicare patients, billed 7,886 HCPCS/CPT codes, and received $383,392 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,417 prescription claims across 606 beneficiaries totaling $503,652 in drug costs, led by Humira(Cf) Pen (Adalimumab). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $33,762 to $503,652. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$263K$526K2018 Medicare payment: $59,804 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $262,438 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $283,935 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $525,808 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $523,060 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $405,044 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $383,392 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
20183441,178$59,804
20199035,669$262,438
20209246,787$283,935
20211,38910,066$525,808
20221,39810,892$523,060
20231,4858,388$405,044
20241,5487,886$383,392

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$252K$504K2016 Drug cost: $33,762 (USD; Tot_Drug_Cst)2017 Drug cost: $89,970 (USD; Tot_Drug_Cst)2018 Drug cost: $7,770 (USD; Tot_Drug_Cst)2019 Drug cost: $94,211 (USD; Tot_Drug_Cst)2020 Drug cost: $182,620 (USD; Tot_Drug_Cst)2021 Drug cost: $306,205 (USD; Tot_Drug_Cst)2022 Drug cost: $355,080 (USD; Tot_Drug_Cst)2023 Drug cost: $426,264 (USD; Tot_Drug_Cst)2024 Drug cost: $503,652 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
20163793$33,762
201747123$89,970
2018112190$7,770
2019336817$94,211
20204121,040$182,620
20216341,479$306,205
20225431,391$355,080
20235891,302$426,264
20246061,417$503,652

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more7351,063$90
11102Biopsy of related skin growth, first growth232253$77
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1,0871,491$64
17000Destruction of precancer skin growth, 1 growth8581,311$48
17003Destruction of precancer skin growth, 2-14 growths5952,636$6

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Humira(Cf) PenAdalimumab13420$109,073
Dupixent PenDupilumab12336$41,013
FluorouracilFluorouracil1033,214$6,274
MetronidazoleMetronidazole752,111$3,559
TretinoinTretinoin471,575$3,286

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for Brian Andrew Holloway, M.D.?

Tedicare shows public-source Medicare data for Brian Andrew Holloway, M.D. (NPI 1558781807), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brian Andrew Holloway, M.D. have ACO affiliation data?

Brian Andrew Holloway, M.D. is shown with ACO affiliation data for Sutter Medicare Direct (MSSP, ACO ID A5279).

What billing organization is linked to Brian Andrew Holloway, M.D.?

Brian Andrew Holloway, M.D. is linked to SUTTER BAY MEDICAL FOUNDATION (billing NPI 1013950807) in the available physician profile data.

Does Brian Andrew Holloway, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.